Chimerix traded at $0.99 this Tuesday April 9th, decreasing $0.01 or 1.00 percent since the previous trading session. Looking back, over the last four weeks, Chimerix lost 20.16 percent. Over the last 12 months, its price fell by 20.80 percent. Looking ahead, we forecast Chimerix to be priced at 0.96 by the end of this quarter and at 0.88 in one year, according to Trading Economics global macro models projections and analysts expectations.
Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. The Company has two clinical-stage product candidates, dociparstat sodium (DSTAT) and brincidofovir (BCV). DSTAT is a heparin derivative that enables dosing at higher concentrations to achieve anti-inflammatory. DSTAT is in development as a potential first-line therapy in acute myeloid leukemia (AML) and as a potential treatment for acute lung injury (ALI) in Coronavirus disease 2019 (COVID-19) patients. BCV is an investigational lipid conjugate that is in development as a medical countermeasure for smallpox. The Company’s other pipeline candidates include ONC201, ONC206, ONC206 and ONC212.